A number of factors, such as the rising cases of chronic disorders, increasing importance of generic drugs, and growing geriatric population, are expected to propel the active pharmaceutical ingredient market at a CAGR of 6.9% during the forecast period (2021–2030). According to P&S Intelligence, the market value will surge from $184,311.2 million in 2020 to $357,005.7 million by 2030. The World Health Organization (WHO) defines an API as any substance or mixture of substances that is used in finished pharmaceutical products that brings about the desired effect inside the body.

The growing prevalence of chronic diseases, such as cardiovascular diseases (CVDs), cancer, respiratory diseases, and diabetes, is one of the most-prominent growth drivers for the market. According to the WHO, around 17.9 million, 9.3 million, 4.1 million, and 1.5 million deaths around the world are caused due to CVDs, cancer, respiratory diseases, and diabetes, respectively, every year. These four diseases collectively account for more than 80% of all the premature non-communicable disease (NCD) deaths.

Request for sample pages of this report: https://www.psmarketresearch.com/market-analysis/active-pharmaceutical-ingredient-api-market/report-sample

In addition, the rising aging population, on account of the increasing life expectancy and declining death rates, will steer the active pharmaceutical ingredient market growth in the forecast years. As the elderly population has a vulnerable immune system, it requires a longer recovery time and intensive care, which can be delivered through advanced API products. The United Nations Department of Economic and Social Affairs (UNDESA) forecasts that the population of people aged 65 years and above will surge from 727 million in 2020 to around 1.5 billion by 2050.

The therapeutic application segment of the active pharmaceutical ingredient market is classified into diabetes, pain management, oncology, communicable diseases, CVDs, respiratory diseases, and others. Under this segment, the oncology category generated the highest revenue in 2020 due to the surging incidence of cancer and escalating demand for highly potent APIs (HPAPIs). The International Agency for Research on Cancer (IARC) estimates that 2,261,419 breast cancer, 865,630 colorectum cancer, 770,828 lung cancer, 604,127 cervix uteri cancer, and 448,915 thyroid cancer cases were diagnosed in females across the world in 2020.

Currently, players in the active pharmaceutical ingredient market are engaging in product launches and facility expansions to consolidate their position. For instance, in January 2021, Sanofi launched EUROAPI, a new company, for developing, producing, and marketing APIs in Europe. APIs manufactured and supplied by the new company will be for patients in Europe and outside. Furthermore, in May 2021, Sandoz, a division of Novartis AG, unveiled its plan to expand its production capacities in Palafolls, Spain; and Kundl, Austria.

Browse detailed report on Active Pharmaceutical Ingredient Market Size, Share, Growth and Demand Forecast to 2030

Geographically, the North American region is expected to account for the largest share in the active pharmaceutical ingredient market during the forecast period owing to the rising prevalence of chronic diseases, increasing number of research and development (R&D) activities, surging technological developments, soaring government focus on generic drugs, and burgeoning demand for specialty drugs and biologics. Besides, the mounting public awareness about lifestyle-related diseases, such as diabetes, will facilitate the market growth in the region.

Thus, the booming geriatric population and increasing cases of chronic ailments are the key contributors to the market growth.

Active Pharmaceutical Ingredient Market Size Breakdown by Segment

Market Segmentation by Type of Manufacturer

Captive
Merchant

Market Segmentation by Type

Generic APIs
Innovative APIs

Market Segmentation by Type of Synthesis

Biotech
Synthetic

Market Segmentation by Type of Drug

Prescription Drugs
Over-The-Counter (OTC) Drugs

Market Segmentation by Therapeutic Application

Communicable Diseases
Oncology
Diabetes
Cardiovascular Diseases (CVDs)
Pain Management
Respiratory Diseases
Others

Market Segmentation by Distribution Channel

Offline
Online

Market Segmentation by Region

North America API Market
By type of manufacturer
By type
By type of synthesis
By type of drug
By therapeutic application
By distribution channel
By country – U.S. and Canada
Europe API Market
By type of manufacturer
By type
By type of synthesis
By type of drug
By therapeutic application
By distribution channel
By country – Germany, France, U.K., Italy, Spain, and Rest of Europe
Asia-Pacific (APAC) API Market
By type of manufacturer
By type
By type of synthesis
By type of drug
By therapeutic application
By distribution channel
By country – Japan, China, India, Australia, South Korea, and Rest of APAC
Latin America API Market
By type of manufacturer
By type
By type of synthesis
By type of drug
By therapeutic application
By distribution channel
By country – Brazil, Mexico, and Rest of LATAM
Middle East and Africa API Market
By type of manufacturer
By type
By type of synthesis
By type of drug
By therapeutic application
By distribution channel
By country – Saudi Arabia, South Africa, and Rest of MEA

Market Segment Analysis of Countries

U.S. API Market
By type of manufacturer
By type
By type of synthesis
By type of drug
By therapeutic application
By distribution channel
Canada API Market
By type of manufacturer
By type
By type of synthesis
By type of drug
By therapeutic application
By distribution channel
Germany API Market
By type of manufacturer
By type
By type of synthesis
By type of drug
By therapeutic application
By distribution channel
France API Market
By type of manufacturer
By type
By type of synthesis
By type of drug
By therapeutic application
By distribution channel
U.K. API Market
By type of manufacturer
By type
By type of synthesis
By type of drug
By therapeutic application
By distribution channel
Italy API Market
By type of manufacturer
By type
By type of synthesis
By type of drug
By therapeutic application
By distribution channel
Spain API Market
By type of manufacturer
By type
By type of synthesis
By type of drug
By therapeutic application
By distribution channel
Japan API Market
By type of manufacturer
By type
By type of synthesis
By type of drug
By therapeutic application
By distribution channel
China API Market
By type of manufacturer
By type
By type of synthesis
By type of drug
By therapeutic application
By distribution channel
India API Market
By type of manufacturer
By type
By type of synthesis
By type of drug
By therapeutic application
By distribution channel
Australia API Market
By type of manufacturer
By type
By type of synthesis
By type of drug
By therapeutic application
By distribution channel
South Korea API Market
By type of manufacturer
By type
By type of synthesis
By type of drug
By therapeutic application
By distribution channel
Brazil API Market
By type of manufacturer
By type
By type of synthesis
By type of drug
By therapeutic application
By distribution channel
Mexico API Market
By type of manufacturer
By type
By type of synthesis
By type of drug
By therapeutic application
By distribution channel
Saudi Arabia API Market
By type of manufacturer
By type
By type of synthesis
By type of drug
By therapeutic application
By distribution channel
U.A.E. API Market
By type of manufacturer
By type
By type of synthesis
By type of drug
By therapeutic application
By distribution channel

Browse Other Related Reports

Generic Drugs Market – Geographically, the Asia-Pacific generic drugs market held the largest share in 2019, and it is also projected to maintain the same trend during the forecast period. This can be due to the surging disposable income, increasing prevalence of chronic diseases, growing geriatric population, increasing number of government initiatives to promote generics usage, and rising healthcare spending in regional countries.

Precision Medicine Market – Globally, the North America held the largest share in 2019, and it is expected to continue its dominance during the forecast period. This is due to the rising incidence of lifestyle-associated and chronic diseases, like CVDs and diabetes, burgeoning healthcare spending, and increasing number of government initiatives in the form of awareness programs and funding for precision medicine.

Media Contact
Company Name: P&S Intelligence
Contact Person: Abhishek
Email: Send Email
Phone: +918887787886
Address:Noida Sector 2
City: Noida
State: UP
Country: India
Website: https://www.psmarketresearch.com/market-analysis/active-pharmaceutical-ingredient-api-market